Summary Expression of tissue factor (TF), a cellular initiator of the extrinsic coagulation cascade, is a feature of many malignant tumours and is intimately involved in the process of metastasis. SW-480 human colon adenocarcinoma cells responded to thrombin (1 U mM') or phorbol 12-myristate 13-acetate (PMA, 0.1 rM) with a 6.0-fold and a 7.7-fold increase in their procoagulant activity (PCA), respectively, after 4-6 h incubation in serum-free medium. The thrombin-enhanced PCA was significantly inhibited by complexing of thrombin with hirudin, or by senne protease inhibition with 3,4-dichloroisocoumarin. Both effects of thrombin and PMA on PCA in SW-480 cells were blocked by pretreatment of cells with cycloheximide or actinomycin D, indicating that the response required de novo protein and RNA synthesis. The thrombin-enhanced PCA depended on the activation of protein kinase C (PKC) as it was diminished by staurosponne and calphostin C. Moreover, stimulation of SW-480 cells by thrombin or PMA led to a significant increase in TF mRNA within 3 h as measured by the reversetranscription PCR method, which was also dependent on the activation of PKC. The unattered decay rate of thrombin-enhanced TF mRNA, evaluated after the addition of staurosporine, suggested that its inhibitory effect occurred at a transcription level. Our data suggest that thrombin enhances TF gene expression and protein synthesis in tumour cells in vitro via PKC activation. The induction of TF expression in tumour cells by thrombin indicates that tumour-associated PCA might have a positive-feedback effect on in vivo local propagation of thrombus by thrombin formation.
surface assemblv of coagulation protease cascade. finally leading to formation and deposition of fibnrn (Altieri and Edgington. 1988) . The constitutively expressed TF is preferentially detectable in the extravascular cells of many tissues (Drake et al. 1989 : Fleck et al. 1990 ) such as epidermis. cerebral cortex. kidney glomeruli. mucosal epithehial lavers and adventitia of -essels. Within the xasculature. endothelium lacking TF under physiological conditions can be stimulated bv endotoxins. thrombin or cytokines to start de novo TF synthesis (Brox et al. 1984 : Edgington et al. 1991 : Tijburg et al. 1991 . Similar results have been found in monocytes.
in which TF synthesis is stimulated by a variety of inflammatorx mediators and antigen-specific cellular immune responses (Edgington et al. 1991 ) . Howe%-er. little is known about the regulatory mechanisms of constitutive TF expression detected in the cells of certain malignant tumours (Callander et al. 1992 : Chiang etal. 1994 .
It has been known that most cancer patients manifest signs of hypercoagulability and some develop thromboembolic disease (Bick. 1992: Rickles et al. 1992 ). There is evidence that systemic or local actix ation of blood coagulation promotes metastasis. whereas inhibition of the blood-clotting cascade favours the host and diminishes metastatic spread (Honn and Sloane. 1984) . Therefore. it has been suggested that an efficient metastasis of tumour cells is possibly dependent on the plasma coagulation cascades. Tumour-associated procoagulant activity (PCA) is thought to lead to local thrombin generation and peritumour fibrin formation in the presence of an intact local coagulation pathway. which has been considered a potentially important characteristic in the malignant state (Zacharski et al. 1990) . Although an alternative pathway exists to activate coagulation. including a tumour cell proteinase-designed cancer procoagulant (Gordon et al. 1975) . the in vixo activation of this proteinase system predominantly proceeds xia the TF pathway (Daxie et al. 1991) arising from constitutive TF expression in a varietv of tumour cell lines.
Indeed. the role of TF in promoting metastasis has been shown in a melanoma metastasis model (Fidler. 1986 : Mueller et al. 1992 ) in which melanoma cell lines expressing high levels of TF exhibited metastasis stronglv. whereas the metastatic potential of the cell lines could be inhibited by treatment with an anti-TF MAb that blocked its PCA. These results suggested that certain component(s) of the coagulation cascade might mediate the metastasis effect of TF expression on tumour cells. Thrombin. a pluripotent bioregulatorv senine proteinase. has been reported to enhance the metastatic phenotype of mammary tumour cells by inducingy their proliferative response (Medrano et al. 1987 ) and found to be a potent mitogen for tumour cells (Bruhn and Zurborn 1983) . Adhesion of tumour cells to platelets (Nierodzik et al. 1991 (Nierodzik et al. . 1992 .
endothelium (Wojtukiewicz et al. 1993 ) and the subendothelial matrix (Klepfish et al. 1993 ) has also been reported to be stimulated by thrombin. Furthermore. it has been reported that 1121 thrombin-treated tumour cells markedly enhanced pulmonary metastasis (Nierodzik et al. 1991 (Nierodzik et al. . 1992 . Our previous study showed that thrombin enhanced the adhesive and migratory activities of SW480 cells via up-regulated 03 integrin expression (Chiang et al, 1996) . In addition, thrombin was shown to mediate tumour cell-induced platelet aggregation (TCIPA) owing to TF activity expression on SW480 cells (Chiang et al, 1994) , which might be important for successful metastasis to occur (Cavanaugh et al, 1988) .
The aim of our present study is to explore the possible regulation of TF expression in SW480 human adenocarcinoma cells. Thrombin was found to induce TT mRNA and protein synthesis in SW480 cells rapidly and markedly, which is dependent on activation of protein kinase C (PKC). 
Measurement of procoagulant acivity
The procoagulant activity (PCA) of cell preparations was measured by plasma recalcification time (Chiang et al, 1994) .
After thawing, the cell pellets were lysed with 30 l of 16 mM octyl-o-D-glycopyranoside at 37°C for 10 min and diluted in 70 tl of 25 mM Hepes-saline (flossel et al, 1992) . Platelet-poor plasma was prepared from whole blood collected from healthy human volunteers and mixed with 3.8% (w/v) sodium citrate (9:1, v/v). In the coagulation assay, 100 ILI of normal citrated plasma was incubated with 100 jlI of the cell lysate for 2 min at 370C. Thereafter, 100 1 of prewarmed 25 mm calcium chloride was added, and the plasma clotting time was determined by a fibrometer (Coag-amate, Organon Teknika, NC, USA). The time recorded was converted to milliunits (mU) per 5 x 104 cells of PCA by reference to a standard curve constructed with serial dilutions of a commercial thromboplastin (Simplastin, Organon Teknika, USA). The amount of thromboplastin required to produce a clotting time of 17 s was arbitarily assigned as one PCA unit To determine the role of the TF-factor ViN/Vla pathway in the PCA, normal human plasma was replaced in some experiments by a factor VII-deficient plasma. In other control experiments, cells were incubated with phospholipase C (1 U ml') at 370C for 15 min before the clotting assay.
Flow cytometric analysis
Flow cytometric studies were performed to quantify surface expression of TF antigen (Chiang et al, 1996) . SW480 cells were stimulated with thrombin (1 U ml-l) for 4 h at 370C, detached British Joumal of Cancer (1998) Fpre 5 Effect of throfbin and PMA on TF mRNA lvels in SW-480 cels as revealed by RT-PCR analysis Total celar RNA (2-3 gg) was reverse rancribe and then amplified usng TF-and G pactinecfifc prmers. The molecular size was determined using Haell DNA molecular marker. PCR products of TF and Gfl-actin mRNA were from SW-480 cels cultured for 1, 3, 5 and 7 h in sern-free DMEM alone (anes 1-4 respely), in the presence of 1 U mf'thronbin for 1, 3, 5 and 7 h (lanes 5-8 respectively), or 0.1 pw PMA for 1, 3, 5 and 7 h (lanes 9-12 respectively).
Transcript stability analysis
The effect of staurosporine on TF mRNA stability was examined by inhibiting mRNA transcription with actinomycin D. After incu- constitutive PCA measured by clotting assay (Figure 1 ) nor the molecular TF expression assayed by flow cytometric analysis (data not shown). No PCA was generated when factor VIl-deficient plasma instead of normal plasma was used in the clotting assay.
Enha e nt of PCA by thrombin and phorbol ester on SW-480 cells
To study the time course of thrombin-stimulated TF expression. SW-480 cells were cultured with thrombin (1 U ml') over a period of 0-48 h, then PCA of these treated cells was analysed. Figure I shows that a significant increment of PCA was observed after 2-hincubation, reaching the maximum at 4-6 h. gradually declining to the basal value within 48 h. During a 4-h incubation, stimulation of SW-480 cells with various concentrations of thrombin exhibited a bell-shaped dose-response curve in enhancing PCA with a peak at 1 U ml' (Figure 2A ). The maximal effect was approximately sixfold. After the treatment of 1 U ml thrombin for 4 h at 370C, an increased expression of TF antigen within the cell population was found by flow cytometric analysis (data not shown). It has been reported that the activation of protein kinase C (PKC) is involved in tumour metastasis and induction of TF expression in monocytes (Temisien et al, 1993 ) and epithelial cells (Terry et al, 1996) . Therefore we examined the effect of phorbol 12-myristate 13-acetate (PMA), a phorbol ester directly stimulating PKC, on SW480 TF expression. As shown in Figure 2B . PMA exhibited a bell-shaped dose-response curve in increasing PCA with a maximal 7.7-fold effect at 0.1 g. On the other hand, neither thrombin-nor PMA-stimulated SW-480 cells were capable of inducing PCA in factor VII-deficient plasma, and the enhanced PCA was reconfumed as increased expression of TF by the observation that the enhanced PCA was lost in the presence of phospholipaseC(l Uml-').
Effects of thrombin inhibitors and metabolic inhibitors on thrombin-enhanced PCA Figure 3 shows results of various inhibitors on thrombin-enhanced TF activity. When thrombin was coupled with hirudin. a specific Britsh Journal of Cancer (1998) 78(9) Figure 5 ). The identity was further established by the cleavage of the 280 bp band by EcoRI into approximately 180-and 100-bp fragments. Whereas the contents of G,B-actin mRNA remained unchanged. TF mRNA levels in the control (unstimulated) cells decreased in a time-dependent manner after replacement of serum-free medium. However. following stimulation with thrombin (1 U ml-') or PMA (0.1 tm). TF mRNA increased greatly at 3 h incubation and decreased at 5-7 h ( Figure 5 ). Quantification by densitometry of the amplified TF species and companson with the G$-actin species demonstrated that TF mRINA was increased 1.9-and 2.1-fold by thrombin and PMA respectively. at 3 h incubation.
Effect of thrombin inhibitors on thrombin-enhanced TF mRNA levels
We compared TF mRNA levels in SW480 cells stimulated with thrombin. hirudin coupled-thrombin or 3.4-DCI-treated thrombin. In contrast to thrombin-enhanced TF mRNA. either hirudinthrombin or 3.4-DCI--thrombin used at the same concentration as actis e thrombin showed a sianificantly decreased TF mRNA expression in SW480 cells (0.4-and 0.5-fold respectixelsv.
Effect of PKC inhibitors on thrombin-enhanced TF mRNA levels PKC inhibitors were used in conjunction with thrombin to identify the signal transduction pathways involved in the regulation of TF gene expression. SW-480 cells treated with increasing concentrations of either staurosporine (0.25-1 -NM) or calphostin C (1.25-5 gm) showed a dose-dependent decrease in the production of TF mRNA. Table 1 showed the quantitative results of the inhibitors' effects of staurosporine and calphostin C on thrombin-enhanced TF mRNA expression in SW-480 cells.
Effect of staurosporine on TF mRNA stability After incubation with thrombin for 2 h. transcription was arrested by actinomycin D and further incubation was performed with or x-ithout the addition of staurosporine (1 JIm). The disappearance of TF mRNA with time was analysed by RT-PCR with scanning densitometr'. As shown in Figure 6 . the yield of mature 2.8-kb TF mRNA fell in a similar way in the presence or absence of staurosporine. A 50%c decrease in TF mRNA was detected at about 1.5 h in both conditions. suggesting that the addition of staurosporine after the arrest of transcription did not modify the disappearance rate of TF mRNA.
DISCUSSION
Experimental evidence suggests that blood coagulation is activated at the site of tumour cell lodgement and plays a role in the pathology of metastatic tumour growth. Procoagulant activitx produced by tumour cells has been implicated in this process (Amirkhosravi et al. 1995 (1998) 78 (9), 1121-1127 u growth factor or inducing neovascularization because of its role in TCIPA and fibrin formation (Nierodzik et al, 1991; Zacharski et al, 1990; Chiang et al, 1995 (Galdal et al, 1985; Bartha et al, 1993) . A similar effect was also reported in cultured vascular smooth muscle cells (Taubman et al, 1993) . The data presented here show that the PCA of SW-480 human colon adenocarcinoma cells was up-regulated by thrombin as well as by PMA. The thrombinenhanced PCA was inhibited by phospholipase C and was not expressed when tested in factor VII-deficient plasma, thus confirning that the up-regulated PCA was due to the enhanced TF activity of SW-480 cells. This is consistent with the previous observation that close association with certain membrane phospholipids is essential for the functional activity of TF, as phospholipase C tratment destroyed procoagulant activity of TF in monocytes and renal glomeruli (Otnaess et al. 1972; Komberg et al, 1994; Tipping et al, 1998) . The time-and dose-dependent manner of thrombin in enhancing PCA suggests a thrombin receptor-mediated mode of action, but the identification of the receptors and their role in mediating thrombin-enhanced TF activity are not known. However, we found that the active site of seine residue in thrombin molecule was a prerequisite for its full expression on TF activity, as ptreatment of thrombin with hirudin or 3,4-DCI resulted in a lower potency than the native thrombin. In addition, recent data suggested that the effect of thrombin on inducing TF mRNA levels in endothelial cells might be at least partly mediated through 'tethered ligand' thrombin receptor (Deguchi et al, 1997; Bartha et al, 1993) Thrombin-and PMA-enhanced TF activity showed a bellshaped dose-response curve with optimal concentration at 1 U mn-' and 0.1 tM respectively. At higher concentrations, both agonists enhanced less TF activity. In addition, the same profile was found for TF antigen (data not shown). The mechanism by which high concentrations of both agonists induced a decrease in TF activity and antigen is unclear, although PMA has been reported to shed TF from the cell membrane (Brozna and Carson 1988) . Several observations have suggested that PKC is involved in mediating the cellular effects of thrombin (Herrick-Davis et al, 1997; Gomez et al, 1988) . To determine whether the effects involved PKC or other protein kinases, the inhibitors tested were staurosporine and calphostin C. Staurosporine interferes with the ATP-binding sites of PKC, whereas calphostin C appears to interfere with the phospholipid-binding regulatory site and is much more specific for PKC when used appropriately (Bruns et al, 1991 (Liu et al, 1992) . To date only initial investigations have been made into the modulation of constitutive TF expression in other systems. In COS-7 cells, expressing high levels of TF in culture, a novel serum response element has been found in the TF promoter region (Mackman et al, 1990) . In general, the TF gene has been classified as an immediate early gene responsive to serum, purified growth factors or certain hormones, which has suggested that TF may participate in biological processes other than haemostasis, including cell proliferation, inflammatory responses, wound healing and the effector limb of the immune system. Whereas the PKC inhibitor-induced decrease in T mRNA supports the possibility of a decrease in TF wanscription, the method of RNA analysis used could not distinguish between an effect on the wanscription rate and/or an effect on TF mRNA stability. As TF mRNA stability was unaffected by the addition of staurosporine after arrest of transcription by actinomycin D, a post-transcriptional mechanism induced by this inhibitor is unlikely to be involved in the decrease in TF mRNA levels. These results are in accordance with those obtained with other genes, stating that stability is unaffected by treatment with H7, a specific PKC inhibitor. In contrast, the decay rate of tumour necrosis factor a mRNA is greatly enhanced by PKC inhibitor, which significantly increases the rate of poly(A) removal from tumour necrosis factor a mRNA, thus facilitating its degradation (Lieberman et al, 1992 ).
In conclusion, our results suggest that thrombin-enhanced TF expression in SW-480 human colon adenocarcinoma cells involves PKC activation. Staurosporine-suppressed TF mRNA was not associated with an apparent alteration in its stability, suggesting that the effect is mainly attributable to a decrease in transcription. As the enhancement of TF expression in tumour cells by thrombin may contribute to the haematogenous phase of metastasis, furter investigation of the intracellular signalling pathways involved in thrombin-enhanced TF synthesis will open up the possibility of modulating this response.
